The side-effect profiles of anidulafun-gin and its comparator, fluconazole, seem very similar (Table 4). In clinical studies, oral fluconazole canadian was associated with a higher incidence of hepatic ADEs than anidulafungin, although these differences are probably not clinically significant.
Continue reading " Anidulafungin (Eraxis): ADVERSE DRUG REACTIONS "
Esophageal Candidiasis Krause and colleagues conducted a multicenter, randomized, double-blind, double-dummy, non-inferiority study to compare the efficacy and safety of IV anidulafungin and oral fluconazole (Diflucan drug, Pfizer) for the treatment of esoph-ageal candidiasis. The study took place in the U.S., South Africa, Thailand, and Argentina. A total of 300 patients were randomly assigned to [...]
Continue reading " Anidulafungin (Eraxis): CLINICAL TRIALS "
Anidulafungin is an echinocandin anti-fungal agent used for intravenous (IV) infusion. It is chemically designated as C58H73N7O17, and its molecular weight is 1140.3. This white to off-white lyophilized powder is available as a single-use, 50-mg vial that is supplied with an accompanying 15-ml diluent vial (20% weight in weight [w/w] dehydrated alcohol in water, or [...]
Continue reading " Anidulafungin (Eraxis): CHEMISTRY AND PHARMACOLOGY "
INTRODUCTION Over the last 25 years, the incidence of fungal infections has increased dramatically. Predominantly a nosocomial complication, invasive fungal infections are growing in the expanding population of at-risk hospitalized patients. The greatest risk lies in the ever-increasing number of immunocompromised patients, including patients with human immunodeficiency virus (HIV) infection and those receiving chemotherapy or [...]
